LncRNA-p21 alters the antiandrogen enzalutamide-induced prostate cancer neuroendocrine differentiation via modulating the EZH2/STAT3 signaling

Luo, Jie; Wang, Keliang; Yeh, Shuyuan; Sun, Yin; Liang, Liang; Xiao, Yao; Xu, Wanhai; Niu, Yuanjie; Cheng, Liang; N. Maity, Sankar; Jiang, Runze; Chang, Chawnshang

doi:10.1038/s41467-019-09784-9

Public

LncRNA-p21 alters the antiandrogen enzalutamide-induced prostate cancer neuroendocrine differentiation via modulating the EZH2/STAT3 signaling

Published in Nature Communications • Jun 12, 2019

Authors:

Jie Luo

Keliang Wang

Shuyuan Yeh

Abstract

While the antiandrogen enzalutamide (Enz) extends the castration resistant prostate cancer (CRPC) patients' survival an extra 4.8 months, it might also result in some adverse effects via inducing the neuroendocrine differentiation (NED). Here we found that lncRNA-p21 is highly expressed in the NEPC ...

Subject

Enzalutamide

Neuroendocrine differentiation

EZH2

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!